Both in Pharmaceuticals
MacroGenics vs Atrium Therapeutics
Over the past year MGNX returned +45.3% and RNA returned −87.6%; their daily moves had a correlation of 0.00.
MGNX +45.3% RNA −87.6%Growth of $1, one year, split-adjusted
| Metric | MGNX | RNA |
|---|---|---|
| Price | $2.30 | $8.66 |
| Market cap | $146.2M | $148.1M |
| Today | −1.50% | −0.69% |
| 1 month | −37.0% | +8.4% |
| 6 months | −23.8% | −33.8% |
| Year to date | +42.5% | −88.0% |
| 1 year | +45.3% | — |
| Revenue growth (YoY) | +378.0% | −21.9% |
| Gross margin | 100.0% | 100.0% |
| Net margin | 59.4% | −672.0% |
| P/E (TTM) | — | — |
| Price / sales | 0.9× | 4.1× |
| Net cash | $173.3M | $263.9M |
| Dividend yield | — | — |
| Volatility (60d) | 113.6% | 65.8% |
| Short % of float | 8.2% | 22.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).